Global Hormone Replacement Therapy Market Size (2024 - 2029)

Hormone Replacement Therapy Market Analysis

The Global Hormone Replacement Therapy Market size is estimated at USD 24.41 billion in 2024, and is expected to reach USD 33.36 billion by 2029, growing at a CAGR of 6.40% during the forecast period (2024-2029).

Specific factors that are positively affecting the hormone replacement therapy (HRT) market growth are increasing awareness of post-menopausal issues among women, the rise in drug development with novel delivery systems, and hormonal imbalance disorders such as acromegaly, hypothyroidism coupled with the rising geriatric population.

Increasing awareness of post-menopause issues is driving the hormone replacement therapy (HRT) market; as women become more informed, they seek tailored solutions for managing symptoms like vasomotor, mood swings, and osteoporosis, driving demand for HRT options. For instance, observed annually on October 28, World Menopause Day aims to highlight the complexities of menopause and its associated health risks. This initiative promotes open discussions between women and healthcare professionals, emphasizing the importance of resource sharing and enhancing the understanding of menopause and its management.

Similarly, the Government of Ireland rolled out Phase 2 of its Menopause Awareness campaign. The Department of Health amplified its efforts to foster open discussions and elevate awareness about menopause. This second phase introduced a television advertisement, complemented by outreach through national and local radio, newspapers, and magazines. Additionally, the campaign utilized out-of-home advertising on digital displays and bus shelters, along with targeted posts on social media. Budget 2023 eliminated VAT from hormone replacement therapy (HRT) to enhance equality of access. Thus, such campaigns increase awareness and education on menopause health issues and inform women about menopause symptoms and the benefits of HRT, thereby contributing to the market growth.

The increasing product launches by the market players and regulatory approval by the US FDA and other regulatory authorities are anticipated to spur market growth during the forecast period. For instance, in June 2023, Pfizer Inc. and OPKO Health Inc. revealed that the United States Food and Drug Administration (FDA) approved NGENLA (somatropin-gala). This once-weekly human growth hormone analog is indicated explicitly for pediatrics aged three years and older, addressing growth failures stemming from insufficient endogenous growth hormone secretion. Essentially, NGENLA (somatrogon-ghla) replenishes the body's deficient growth hormone. Thus, approval by regulatory authorities such as the FDA is expected to increase access to this drug and will likely propel the demand for this HRT, contributing to the segment's growth.

Thus, all factors above, such as increased awareness of menopause issues, the launch of awareness campaigns to educate women about menopause symptoms and available therapies, and the introduction of new products, are expected to propel the market's growth during the forecast period. However, the high cost of hormone replacement therapy and the risk of developing cancer from HRT are anticipated to hamper market growth globally.

Hormone Replacement Therapy Industry Segmentation

As per the scope of the report, hormone replacement therapy (HRT) is a treatment technique for replacing or replenishing hormones in the human body that are at inadequate levels than those required for the normal physiology of the human body. The most prominent application of HRT is in the treatment of symptom alleviation of menopause.

The hormone replacement therapy market is segmented by therapy, route of administration, indication, and geography. By therapy, the market is segmented as estrogen hormone replacement, growth hormone replacement, thyroid hormone replacement, and testosterone replacement. By route of administration, the market is segmented as oral, parenteral, and other routes of administration. By indication, the market is segmented as menopause, hypothyroidism, growth hormone deficiency, and other indications. By geography, the market is segmented as North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (USD) for all the above segments.